Filing Flows › Industrials › Bruker (BRKR)
Bruker (BRKR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Bruker (BRKR) Q3 2026 earnings results →
Q3 2026 Revenue up 2% year over year to $874M · 13¢ of every $1 of revenue lost · operating margin -10.4%
Bruker made $874M in Q3 2026 (+2% Y/Y): BSIBIOS $397M, Bsi Nano $263M, BSIBMID $134M. Operating margin -10.4%, net loss $110M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $874.0M in Q3 2026, up 2% year over year and up 4% from the previous quarter. BSIBIOS was the largest line at 45% of revenue. Energy and Supercon Technologies added $7.5M year over year (up 10%), 56% of the total change. Bsi Nano declined 1%.
Gross margin was 49.1%, up 5.0 points from Q3 2025. Operating costs exceeded revenue by $91.0M, an operating margin of -10.4%. Operating expenses grew 21% against revenue growth of 2%. The fastest-growing cost line was Other operating costs (+123%). The quarter ended with a net loss of $109.7M, wider than the previous quarter's $50.9M loss.
Operating cash flow was $118.2M. Non-cash charges added back $54.1M of depreciation and amortization and $6.1M of share-based compensation. Working capital and other items added $167.7M. After purchases of property, plant and equipment and intangible assets ($21.5M), free cash flow as the company reports it was $96.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $874M | +2% | -10.4% | −$110M | $118M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $838M | +5% | -7.8% | −$50.9M | −$77.4M |
| Q1 2026 | 10-Q | May 7, 2026 | $823M | +3% | 1.2% | $14.4M | $71.2M |
| Q4 2025 | 10-K | Feb 27, 2026 | $977M | -0.2% | 7.8% | $26.0M | $230M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $860M | -0.5% | -6.0% | −$58.5M | −$33.2M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $797M | -0.4% | 1.5% | $7.6M | −$128M |
| Q1 2025 | 10-Q | May 7, 2025 | $801M | +11% | 4.0% | $17.4M | $65.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bruker
We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Our technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy technologies.
In its own words, from its 10-K, filed Feb 27, 2026.
Bruker against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +4%. Operating margin: -10.4% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
| TXG 10x Genomics | Q3 2026 | $151M | +1% | -10.7% |
Source: Bruker 10-Q on SEC EDGAR · CIK 1109354 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns BRKR and who is buying
More on BRKR
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results